Total Lesion Glycolysis Using $^{18}$F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer

Ji Hyung Hong,¹ Hyon Ho Kim,² Eun Ji Han,³ Jae Ho Byun,¹ Hong Seok Jang,⁴ Eun Kyong Choi,⁵ Jin Hyung Kang,² and Ie Ryung Yoo¹

¹Department of Internal Medicine, Incheon St. Mary's Hospital, Incheon; ²Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul; ³Department of Nuclear Medicine, Daejeon St. Mary's Hospital, Daejeon; ⁴Department of Radiation Oncology, Seoul St. Mary's Hospital, Seoul; ⁵Department of Nuclear Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea

Received: 6 June 2015
Accepted: 15 September 2015

Address for Correspondence:
Ie Ryung Yoo, MD
Department of Nuclear Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Bangbae-dong, Seongdong-gu, Seoul 06591, Korea
Tel: +82.2-2258-1549, Fax: +82.2-2258-1575
E-mail: ryoye@catholic.ac.kr

INTRODUCTION

Esophageal cancer is the third most common malignancy of the digestive tract worldwide (1). In East Asia, the most common type of esophageal cancer is squamous cell carcinoma, which is considered highly radiosensitive. Chemoradiotherapy (CRT) has become an accepted treatment for localized esophageal cancer because it can achieve the same survival benefit as surgical resection in a less invasive manner (2). However, the prognosis of esophageal cancer remains poor, despite recent improvements in the available treatment modalities. The identification of pretreatment prognostic factors for esophageal cancer could improve the treatment strategies and aid in risk stratification.

Positron emission tomography (PET) with 2-deoxy-2-[fluorine-18]fluoro-D-glucose ($^{18}$F-FDG)/computed tomography (CT) is used for esophageal tumor staging before treatment and for the evaluation of tumor response, locoregional recurrence, and distant metastases after treatment. Pretreatment standardized uptake value (SUV) is commonly used as a relative measure of $^{18}$FDG uptake and is considered a prognostic factor for risk stratification; however, it does not reflect the heterogeneity of a tumor (3). To overcome this drawback of SUV, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) have been considered prognostic factors for survival in many cancers. However, their prognostic value for radiotherapy-treated squamous esophageal cancer has not been evaluated. In this study, SUV, MTV, and TLG were measured to predict their prognostic role in overall survival (OS) in 38 esophageal cancer patients who had undergone $^{18}$F-FDG PET/CT before radiotherapy. TLG demonstrated higher sensitivity and specificity for predicting OS than MTV and SUV; and a better OS was observed in patients with low TLG compared to those with high TLG in locally advanced disease (OS, 46.9 months; 95% confidence interval [CI], 33.50-60.26 vs. 25.3 months; 95% CI, 8.37-42.28; $P = 0.003$). Multivariate analyses in these patients determined that TLG and the use of combination chemotherapy were the independent prognostic factors for OS (hazard ratio [HR], 7.12; 95% CI, 2.038-24.857; $P = 0.002$ and HR, 6.76; 95% CI, 2.149-21.248; $P = 0.001$, respectively). These results suggest that TLG is an independent prognostic factor for OS and a better predictor of survival than MTV and SUV in patients with locally advanced esophageal cancer treated with radiotherapy.

Keywords: Total Lesion Glycolysis; Metabolic Tumor Volume; Esophageal Neoplasms, $^{18}$F-FDG PET/CT

MATERIALS AND METHODS

Patient population, treatment, and response evaluation

Eighty-nine patients with pathologically confirmed esophageal cancer, who did not show any evidence of distant metastasis, received radiotherapy with or without chemotherapy as an initial treatment in Seoul St. Mary’s hospital, Incheon St. Mary’s.
hospital, and St. Vincent hospital between January 1, 2009 and December 31, 2013. Among them, 38 patients who were evaluated by pre-treatment $^{18}$F-FDG PET/CT were included in this study.

Radiation was delivered once daily, 5 days a week for 6-7 weeks. The total radiation dose and concomitant chemotherapy regimen were determined by the physician. Chemotherapy regimens were as follows: The weekly 5-fluorouracil (5-FU)/cisplatin (FP) regimen consisted of an intravenous infusion of 30 mg/m$^2$ cisplatin on day 1, followed by a 24-hr continuous infusion of 200 mg/m$^2$ 5-FU for 5 days every week. The tri-weekly FP regimen consisted of an intravenous infusion of 75 mg/m$^2$ cisplatin on day 1, followed by a 24-hr continuous infusion of 800 mg/m$^2$ 5-FU for 4 days. The weekly cisplatin regimen consisted of an intravenous infusion of 30 mg/m$^2$ cisplatin on day 1 every week. The weekly 5-FU regimen consisted of an intravenous 24-hr continuous infusion of 200 mg/m$^2$ 5-FU for 5 days every week.

Approximately 10-12 weeks after completion of therapy, patient response was assessed by a clinical examination and a chest and abdomen/pelvis CT scan using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. The data regarding patient progression, recurrence, and death were collected from the patients’ medical records. Tumors with invasion to adjacent structures or nodal metastasis were defined as locally advanced disease, while tumors that lacked evidence of invasion to adjacent structures or nodal metastasis were defined as early disease.

$^{18}$F-FDG PET/CT imaging and analysis
PET scanning was performed using routine clinical PET scanning protocols at the 3 participating institutions. The three institutions shared the same methods for patient preparation, FDG preparation, and imaging procedure. All PET/CT images were centrally interpreted and quantitated using single workstation software, Mirada XD3 software (Mirada Medical, Oxford, United Kingdom).

All patients fasted for at least 4-6 hr before evaluation by $^{18}$FDG PET/CT. A dose of 5.5-7.4 MBq/kg body weight of FDG was injected intravenously, and scanning began 60 min later. No patient had a blood glucose level greater than 130 mg/dL before the injection. Studies were acquired on two combined PET/CT in-line systems (Biograph Duo; Siemens Medical Solutions, Knoxville, TN, USA or Discovery STE; GE Healthcare, Milwaukee, WI, USA). The CT scan began at the orbitomeatal line and progressed to the proximal thigh (Biograph Duo; 130 kVp, 80 mA and 5 mm slice thickness; Discovery STE; 140 kVp, auto mA and 3.75 mm slice thickness). The PET scan followed immediately over the same body region. The CT data were used for attenuation correction, and images were reconstructed using a standard ordered-subset expectation maximization algorithm. The axial spatial intrinsic resolution was 6.5 or 5.0 mm at the centre of the field of view.

The images were closely reviewed by 2 nuclear medicine physicians. The maximum SUV (SUVmax) of the primary cancer was measured by placing a volume of interest around the visible tumor, with careful attention to avoid inclusion of FDG-avid non-tumor tissue.

MTV was defined as the summed volume in cubic centimeters (cm$^3$) of the primary cancer and was measured using a semi-automated contouring program computed using Mirada XD3 software. To define the contouring margin of the primary tumor, we used a fixed SUV cut-off value of 2.5. Each identified tumor was then segmented semi-automatically in three dimensions. The tumor boundaries were drawn large enough to incorporate target lesions, and in transaxial, coronal, and sagittal planes reduced to eliminate the confounding influence by physiologically glucose-avid tissues such as the myocardium. Then, an isocountour connecting the outline of the target lesion with a cut-off value of the SUV was set automatically, and all voxels with an SUV over the cut-off value within the isocontour were included in the MTV calculation. After segmentation, the software quantified the final MTV. SUVmax, peak SUV (SUVpeak), and mean SUV (SUVmean) were also calculated. SUVpeak was defined as the average SUV within a circular region of interest 1.2 cm in diameter centered on the maximum value pixel. TLG was calculated as the product of MTV and SUVmean.

Outcome endpoints
To determine the prognostic value of SUVs, MTV, and TLG, overall survival (OS) was used as the clinical endpoint. OS was defined as the time from therapy initiation to death or to the most recent inpatient or outpatient follow-up through May 01, 2014. Patient response to radiotherapy was also analysed. Treatment response was evaluated based on the RECIST v.1.1 (8). Patients were identified as responders, having a partial response (PR) or complete response (CR), or non-responders in the case of stable disease (SD) and progressive disease (PD).

Statistical analysis
Statistical analyses were performed using SPSS software version 19.0 (SPSS, Chicago, IL, USA) and MedCalc version 15.6 (MedCalc, Seoul, Korea). Receiver operating characteristic (ROC) curve analysis was performed to identify the optimal discriminating cut-off values for TLG, MTV, and SUVs to evaluate the accuracy of each metabolic index as a prognostic parameter. Cancer-related death was used as a dependent variable in ROC curve analysis. If the area under the curve (AUC) was not statistically significant, the median value of the metabolic parameter was selected as a cut-off value. A chi-square test and Mann-Whitney U-test were performed to analyse the differences in clinico-
pathological factors and metabolic parameters between responders and non-responders. The log-rank test was used to assess the correlation between OS and TLG, MTV, and SUV. A Cox proportional hazard model was used for multivariate comparisons, and the estimated hazard ratio (HR) and 95% confidence interval (CI) were calculated. All tests were two-sided and \( P \) values < 0.05 were considered statistically significant.

**Ethics statement**

This retrospective analysis was approved by the institutional review boards of The Catholic University of Korea, Seoul St. Mary’s Hospital (No.KC14RISI0037), St. Vincent Hospital (No. VC14OIMI0204) and Incheon St. Mary’s Hospital (No. OCI4RI-SI0144). Because of the retrospective design of this study, the need for informed consent from the patients was waived.

**Table 1. Patient characteristics**

| Characteristics       | Total n = 38 | Responder CR/PR, n = 23 | Non-responder SD/PD, n = 9 | \( P \) value |
|-----------------------|-------------|-------------------------|---------------------------|--------------|
| Age (yr) Median (range) | 68 (35-89) | 67 (35-87) | 61 (45-89) | 0.904 |
| Sex (%)               |             |                         |                           | 0.121 |
| Male                  | 33 (86.8)  | 21 (91.3) | 6 (66.7)  | |
| Female                | 5 (13.2)   | 2 (8.7)   | 3 (33.3)  | |
| Smoking status (%)    |             |                         |                           | 0.648 |
| Ever and current      | 17 (44.7)  | 10 (43.5) | 4 (44.4)  | |
| Never                 | 17 (44.7)  | 12 (52.2) | 2 (22.2)  | |
| N-A                   | 4 (10.6)   | 1 (4.3)   | 3 (33.3)  | |
| Tumor length (range, cm) (%) |         |             |                           | 0.643 |
| < 6                   | 13 (34.2)  | 7 (30.4)  | 3 (33.3)  | |
| ≥ 6                   | 17 (44.7)  | 10 (43.5) | 4 (44.4)  | |
| N-A                   | 8 (21.1)   | 6 (26.1)  | 2 (22.2)  | |
| Site of primary tumor (%) |          |             |                           | 0.248 |
| Cervical              | 3 (7.9)    | 2 (8.7)   | 1 (11.1)  | |
| Upper                 | 7 (18.4)   | 4 (17.4)  | 3 (33.3)  | |
| Middle                | 10 (26.3)  | 6 (26.1)  | 2 (22.2)  | |
| Lower                 | 18 (47.4)  | 11 (47.8) | 3 (33.3)  | |
| T stage (%) 1         | 8 (21.1)   | 3 (13.0)  | 1 (11.1)  | 0.094 |
| 2                     | 13 (34.2)  | 7 (30.4)  | 2 (22.2)  | |
| 3                     | 7 (18.4)   | 9 (39.1)  | 0 (0.0)   | |
| 4                     | 10 (26.3)  | 4 (17.4)  | 6 (66.7)  | |
| N stage (%) 0         | 8 (21.1)   | 5 (21.7)  | 1 (11.1)  | 0.342 |
| 1                     | 13 (34.2)  | 8 (34.8)  | 2 (22.2)  | |
| 2                     | 7 (18.4)   | 3 (13.0)  | 4 (44.4)  | |
| 3                     | 10 (26.3)  | 7 (30.4)  | 2 (22.2)  | |
| Stage (%) I           | 4 (10.5)   | 3 (13.0)  | 0 (0.0)   | 0.227 |
| II                    | 5 (13.2)   | 3 (13.0)  | 1 (11.1)  | |
| III                   | 29 (76.3)  | 17 (73.9) | 8 (88.9)  | |
| Differentiation (%)   |             |             |             | 0.472 |
| Well                  | 5 (13.2)   | 3 (13.0)  | 1 (11.1)  | |
| Moderately            | 22 (57.9)  | 13 (56.6) | 5 (55.6)  | |
| Poorly                | 3 (7.9)    | 1 (4.3)   | 1 (11.1)  | |
| N-A                   | 8 (21.3)   | 6 (26.1)  | 2 (22.2)  | |
| Combined chemotherapy regimen (%) |         |             |                           | 0.815 |
| 5-FU/cisplatin        | 25 (65.8)  | 16 (69.7) | 6 (66.7)  | |
| Cisplatin             | 7 (18.4)   | 3 (13.0)  | 1 (11.1)  | |
| 5-FU                  | 3 (7.9)    | 1 (4.3)   | 2 (22.2)  | |
| Radiotherapy alone    | 3 (7.9)    | 3 (13.0)  | 0 (0.0)   | |
| Pre-treatment Hb (g/dL) (Mean, SD) | 12.6, 1.7 | 12.7, 1.6 | 13.0, 1.7 | 0.662 |
| Pre-treatment albumin (g/dL) (Mean, SD) | 4.0, 0.6 | 4.1, 0.5 | 3.9, 0.6 | 0.443 |
| Pre-treatment LDH (U/L) (Mean, SD) | 100.3, 113.4 | 381.9, 136.9 | 431.0, 106.6 | 0.360 |
| SUVpeak (Mean, SD)    | 10.9, 4.8  | 10.6, 5.7 | 11.2, 2.0 | 0.785 |
| S UVmax (Mean, SD)    | 13.2, 6.1  | 12.9, 7.2 | 13.7, 3.2 | 0.867 |
| S UVmean (Mean, SD)   | 5.4, 1.5   | 5.3, 1.7  | 5.9, 1.0  | 0.249 |
| MTV (Mean, SD)        | 45.38, 36.1 | 39.75, 37.9 | 64.11, 39.1 | 0.098 |
| TLG (Mean, SD)        | 265.50, 221.4 | 229.76, 199.7 | 388.74, 276.8 | 0.107 |

N-A, non-assessable; SD, standard deviation; 5-FU, 5-fluoropyrimidine; Hb, hemoglobin; LDH, lactate dehydrogenase; SUV, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis.
RESULTS

Patient characteristics
The patient characteristics are summarized in Table 1. All patients were diagnosed with squamous cell carcinoma. Thirty-three patients (86.8%) exhibited locally advanced disease. Three patients (7.9%) did not receive chemotherapy during radiotherapy. The median follow-up time was 7.5 months (range, 2.6-87.9). After radiotherapy with or without chemotherapy, CR was observed in 9 patients, PR in 14 patients, SD in 3 patients, and PD in 6 patients. Three patients, 2 with a PR and 1 with SD, underwent an esophagectomy with lymph node dissection with curative intent. Six patients died before the evaluation. By the last follow-up date, 21 patients had died. In those patients who responded to therapy, baseline TLG and MTV were slightly, but not significantly higher than in non-responders (P = 0.107 and 0.098, respectively), whereas no differences in SUVs were detected according to patient response.

ROC curve analysis, AUCs, and cut-off values
The AUCs of TLG, MTV, and SUVmean were 0.695 (P = 0.041, 95% CI, 0.522-0.867), 0.678 (P = 0.046, 95% CI, 0.507-0.820), and 0.609 (P = 0.252, 95% CI, 0.428-0.791), respectively (Fig. 1). The AUCs for SUVmax and SUVpeak were 0.563 (P = 0.509) and 0.583 (P = 0.386), respectively. The difference in the AUC between TLG and MTV, TLG, and MTV and SUVmean were 0.017 (P = 0.559), 0.086 (P = 0.266), and 0.069 (P = 0.469), respectively. A ROC analysis of OS demonstrated that the AUC for TLG was greater than those for MTV or SUVs. Thus, the optimal cut-off value of TLG was 232.98 with 71.4% sensitivity and 76.5% specificity for the dichotomized TLG (≤ 232.98 vs. > 232.98). The optimal cut-off value of MTV was 44.7 cm³ with 61.9% sensitivity and 82.4% specificity for the dichotomized MTV (≤ 44.7 vs. > 44.7). Because there was no statistically significant associations between the AUC of SUVmax, SUVmean, or SUVpeak and OS, the median (5.40, 5.70, and 11.0, respectively) were used as the cut-off values for dichotomization.

Metabolic parameters as prognostic factors for OS
We compared the OS according to the clinicopathological variables and metabolic parameters. The median OS did not significantly differ between patients with early vs. advanced disease. However, patients with advanced T stage tended to have shorter OS compared with those with early T stage (40.8 months, 95% CI, 21.56-60.10 vs. 32.3 months, 95% CI, 20.46-44.20; P = 0.385) (Fig. 2A). The median OS did not significantly differ between patients who received CRT and those who received radiotherapy alone. Among the patients who received CRT, those receiving an FP combination exhibited longer OS than those with 5-FU or cisplatin alone (57.9 months, 95% CI, 40.07-75.75 vs. 14.0 months, 95% CI, 1.46-26.52; P = 0.012).

Next, the patients were dichotomized into two subgroups according to metabolic parameters. Among the total patients, the low TLG group showed a significantly longer OS (45.0 months, 95% CI, 32.98-56.94) compared with the high TLG group (25.3 months, 95% CI, 8.40-42.28; P = 0.004). None of MTV SUVmax, SUV peak, and SUVmean correlate significantly with the OS. In the subgroup analysis according to disease extent, the low TLG group with locally advanced disease exhibited a significantly longer OS compared to the high TLG group (46.9 months, 95% CI, 33.50-60.26 vs. 25.3 months, 95% CI, 8.37-42.28; P = 0.003) (Fig. 2B), whilst the TLG in patients with early disease did not associate with OS. The low MTV group with locally advanced disease tended to have longer OS compared with the high MTV group, however, without statistical significance (39.0 months, 95% CI, 26.37-51.63 vs. 34.6 months, 95% CI, 15.10-54.01; P = 0.054) (Fig. 2C). The MTV in patients with early disease did not associate with OS. None of SUVmax, SUV peak and SUVmean correlated significantly with OS in patients with locally advanced or early disease (Fig. 2D).

Patients who received the combination chemotherapy showed longer OS than those who received a single regimen (54.4 months, 95% CI, 35.681-73.123 vs. 7.03 months, 95% CI, 4.061-9.992; P = 0.008). However, high TLG was significantly associated with reduced OS in patients who received both the combination (P = 0.012).
In the univariate analyses, high TLG was associated with poor OS (HR, 4.69; 95% CI, 1.540-14.281; \( P = 0.007 \)) (Table 2). The use of a 5-FU-based combination regimen was the second most significant prognostic factor for OS (HR, 3.41; 95% CI, 1.295-8.959; \( P = 0.013 \)). In the multivariate analysis, TLG and the use of a combined chemotherapy regimen remained significantly associated with OS in locally advanced esophageal cancer patients (HR, 6.76; 95% CI, 2.149-21.248; \( P = 0.001 \), HR, 4.69; 95% CI, 1.540-14.281; \( P = 0.007 \), respectively). Representative examples of the relationship between TLG are OS are shown in Fig. 3.

**DISCUSSION**

This study investigated the prognostic value of specific metabolic parameters determined from pre-treatment \(^{18}\)F-FDG PET/CT scans in patients with esophageal cancer treated with radiotherapy as the primary treatment. While MTV and SUV did not associate with OS, TLG was found to be an important independent prognostic factor for OS in locally advanced esophageal cancer.

SUV is frequently used to evaluate tumor response and survival outcomes in various cancers such as breast, head and neck, and lung cancers (9-11). The SUV of primary esophageal cancer tumors has been reported to be significantly associated with OS, progression-free survival, local control, and response...
Hong JH, et al. • Total Lesion Glycolysis in Advanced Esophageal Carcinoma

However, in contrast to prior studies, we observed that the primary tumor SUVmax, SUVmean, and SUVpeak were not related to the OS or response to radiotherapy in this study. Song et al. (14) reported that the SUVmax after concurrent CRT was not associated with the pathologic response and Hyun et al. (15) also suggested that SUVmax was not a significant prognostic factor for OS in esophageal cancer. SUVmax reflects only the most active part of the tumor, and therefore does not correlate with the actual tumor burden (16). SUVmean, the mean value of metabolic activity in a chosen region, and SUV peak, the average value within a small, fixed-size region of interest in the tumor, share many of the same limitations as SUVmax (17). Based on the weaknesses of SUV measurements as metabolic parameters of esophageal cancer, volume-based metabolic parameters such as MTV and TLG have been investigated.

MTV and TLG have been reported to be better prognostic factors for survival than SUVs in lung, ovarian, and head and neck cancers, and in pleural mesothelioma (4-7). However, in our study, MTV exhibited a lower AUC than TLG and was not an independent prognostic factor for OS in the multivariate Cox regression analysis.

**Table 2. Cox regression analysis of overall survival in locally advanced esophageal cancer patients (n = 33)**

| Characteristics          | Univariate |          |          | Multivariate |          |          |
|--------------------------|------------|----------|----------|--------------|----------|----------|
|                          | HR         | 95% CI   | P        | HR           | 95% CI   | P        |
| Age (yr)                 |            |          |          |              |          |          |
| ≤ 60                     | 1          |          | 0.551    |              |          |          |
| > 60                     | 1.34       | 0.509-3.545 | 0.287    |              |          |          |
| Gender                   |            |          |          |              |          |          |
| Female                   | 1          |          |          |              |          |          |
| Male                     | 2.99       | 0.399-22.407 | 0.221    |              |          |          |
| Response to radiotherapy |            |          |          |              |          |          |
| CR/PR                    | 1.96       | 0.667-5.753 | 0.085    |              |          |          |
| LDH                      |            |          |          |              |          |          |
| ≤ 410.0                  | 1          |          |          |              |          |          |
| > 410.0                  | 2.32       | 0.890-6.043 |          |              |          |          |
| Hb                       |            |          |          |              |          |          |
| ≤ 13                     | 1          |          | 0.158    |              |          |          |
| > 13                     | 2.09       | 0.751-5.827 |          |              |          |          |
| Differentiation          |            |          |          |              |          |          |
| Well                     | 1          |          | 0.794    |              |          |          |
| Moderate                 | 0.92       | 0.251-3.337 |          |              |          |          |
| Poorly                   | 0.47       | 0.049-4.511 |          |              |          |          |
| Tumor length (cm)        |            |          |          |              |          |          |
| ≤ 6 cm                   | 1          |          | 0.809    |              |          |          |
| > 6 cm                   | 1.41       | 0.085-23.573 |          |              |          |          |
| TNM stage                |            |          |          |              |          |          |
| II                       | 1          |          | 0.990    |              |          |          |
| III                      | 1.01       | 0.233-4.380 |          |              |          |          |
| Chemotherapy regimen     |            |          |          |              |          |          |
| Single                   | 1          |          | 0.013*   | 0.001*       |          |          |
| Combination              | 3.41       | 1.295-8.959 | 6.76     | 2.149-21.248 |          |          |
| SUVpeak                  |            |          |          |              |          |          |
| ≤ 11.0                   | 1          |          |          |              |          |          |
| > 11.0                   | 1.11       | 0.450-2.736 |          |              |          |          |
| SUVmean                  |            |          |          |              |          |          |
| ≤ 5.70                   | 1          |          |          |              |          |          |
| > 5.70                   | 1.12       | 0.454-2.767 |          |              |          |          |
| SUVmax                   |            |          |          |              |          |          |
| ≤ 13.30                  | 1          |          |          |              |          |          |
| > 13.30                  | 0.92       | 0.373-2.264 |          |              |          |          |
| MTV                      |            |          |          |              |          |          |
| ≤ 44.70                  | 1          |          | 0.061    |              |          |          |
| > 44.70                  | 2.34       | 0.962-5.683 |          |              |          |          |
| TLG                      |            |          |          |              |          |          |
| ≤ 232.98                 | 1          |          | 0.007*   | 0.002*       |          |          |
| > 232.98                 | 4.69       | 1.540-14.281 | 7.12     | 2.038-24.857 |          |          |

*Statistically significant. HR, hazard ratio; CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LDH, lactate dehydrogenase; Hb, haemoglobin; MTV, metabolic tumor volume; TLG, tumor glycolysis.

Fig. 3. Representative examples of the relationship between metabolic parameters and overall survival. (A) Representative 18F-FDG PET/CT images of a 52-yr-old female patient with middle esophageal cancer (T3N0, stage IIb) exhibiting a TLG of 673.92, an MTV of 93.6 cm3, and a SUVmax of 21.7. She exhibited progressive disease after 5-fluorouracil/cisplatin chemoradiotherapy and lived for 5.6 months after the diagnosis. (B) Representative 18F-FDG PET/CT images of a 79-yr-old male patient with lower esophageal cancer (T2N1, stage IIB) exhibiting a TLG of 68.64, an MTV of 15.6 cm3, and a SUVmax of 10.5. He exhibited stable disease after radiotherapy alone and lived for 61.8 months after the diagnosis.

SUVmax reflects only the most active part of the tumor, and therefore does not correlate with the actual tumor burden (16).

SUVmean, the mean value of metabolic activity in a chosen region, and SUV peak, the average value within a small, fixed-size region of interest in the tumor, share many of the same limitations as SUVmax (17). Based on the weaknesses of SUV measurements as metabolic parameters of esophageal cancer, volume-based metabolic parameters such as MTV and TLG have been investigated.
Total Lesion Glycolysis in Advanced Esophageal Carcinoma

Hong JH, et al.

Total Lesion Glycolysis in Advanced Esophageal Carcinoma

Hong JH, et al. • Total Lesion Glycolysis in Advanced Esophageal Carcinoma

analysis. Consistent with our results, recent studies have reported that TLG is a more accurate predictor of survival than MTV in lung, head and neck, and gall bladder cancers and in soft tissue sarcoma (16,18-21). TLG, the product of the MTV and SUVmean, simultaneously represents the degree of 18F-FDG uptake and the size of the metabolically active tumor mass. Our study supports TLG as an ideal metabolic parameter for tumor burden, especially in locally advanced esophageal cancer.

Nevertheless, the comparison between TLG and MTV as prognostic factors in esophageal cancer remains controversial. Hatt et al. (22) reported that MTV and TLG are both accurate predictive volumetric parameters for OS. Li et al. (23) also reported that pre-treatment MTV and TLG are useful prognostic factors in non-surgical esophageal cancer. However, it should be noted that 28% (14/50) of the esophageal cancer patients in Hatt et al. study and 100% of the patients in Li et al. study were diagnosed with adenocarcinoma. The differences in SUV, MTV, and TLG between tumor histologies have not yet been investigated in esophageal cancer. In lung cancer, the SUV of tumors with squamous cell histology was higher than that of adenocarcinomas (24). Similarly, in our study, the mean (± standard deviation) SUVmax (13.16 ± 6.1) was higher than that reported by the Hatt et al. (8.0 ± 3.3). However, differences in the SUV do not always equate to differences in MTV and TLG. The differences in tumor histology between these three studies may affect the different prognostic roles of MTV and TLG. Further large-scaled population-based analyses are warranted, including on the effect of tumor histology on metabolic parameters in esophageal cancer.

This study had some limitations. Because 18F-FDG PET/CT for esophageal cancer staging was not performed routinely in our institution, only 38 patients were included in our analysis. This could exert potential selection bias and might induce insignificant survival differences or prognostic roles according to different stages and differentiation. However, because other studies evaluated a more heterogeneous population of patients with respect to tumor stage and histology and the initial treatment modality (12,13,15), the relatively homogeneous patient population with respect to the administration of radiotherapy and tumor histology in the current study compensates for this limitation. Moreover, we measured all intrathoracic tumors with visibly increased 18F-FDG uptake, not differentiating nodal metastases from the primary tumor, because small lymph nodes adjacent to the primary tumor cannot be measured separately in 18F-FDG PET/CT. Patients with lymph node metastasis accounted for 79% of the patients examined. In a recent study of lung cancer, the TLG and MTV of the primary tumor, as well as nodal and distant metastases were associated with OS (7). Further research to define the prognostic roles of TLG within the primary tumor and lymph nodes is on going.

In conclusion, the present study suggests that TLG is an independent prognostic factor for OS and a better predictor of survival than MTV and SUV in patients with locally advanced esophageal cancer treated with radiotherapy as the initial treatment. A new prognostic stratification based on conventional clinicopathological parameters combined with TLG may provide more optimised prognostic information.

DISCLOSURE

The authors have no conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Design of the study: Hong JH, Yoo IR. Investigation of the clinical data: Hong JH, Kim HH. Measurement of the metabolic parameters: Han EJ, Choi EK, Yoo IR. Data analysis: Hong JH, Kim HH. Writing the manuscript: Hong JH, Yoo IR. Final decision to submit and approval of the final manuscript: all authors.

ORCID

Ji Hyung Hong http://orcid.org/0000-0002-0492-3959

REFERENCES

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seebier S, Klump B, Budach W, Teichmann R, Schmitt M, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2510-7.
3. Chan SC, Chang JT, Lin CY, Ng SH, Wang HM, Liao CT, Chang CJ, Lin SY, Yen TC. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nuel Med Commun 2011; 32: 989-96.
4. Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, Ahn MJ, Kim TS, Yi CA, Chung MJ. Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 2010; 17: 2787-94.
5. Chung HH, Kwon HW, Kang KW, Park NH, Song SY, Chung JK, Kang SB, Kim JW. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol 2012; 19: 1966-72.
6. Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med 2012; 53: 709-15.
7. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shihi MC, Shimada N, Chen S, Salgia R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2012; 39: 27-38.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Daney J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.

9. Zhang J, Jia Z, Ragaz J, Zhang YJ, Zhou M, Zhang YP, Li G, Wang BY, Wang ZH, Hu XC. The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer. BMC Cancer 2013; 13: 42.

10. Lin SC, Liao CY, Kao CH, Yen KY, Yang SN, Wang YC, Liang JA, Chen SW. Pretreatment maximal standardized uptake value of the primary tumor predicts outcome to radiotherapy in patients with pharyngeal cancer. J Radiat Res (Tokyo) 2012; 53: 462-8.

11. Davies A, Tan C, Paschalides C, Barrington SE, O’Doherty M, Utley M, Treasure T. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer 2007; 55: 75-8.

12. Atsumi K, Nakamura K, Abe K, Hirakawa M, Shioyama Y, Sasaki T, Baba S, Isoda T, Ohga S, Yoshitake T, et al. Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer. J Radiat Res (Tokyo) 2013; 54: 890-8.

13. Palie O, Michel P, Ménard JF, Rousseau C, Rio E, Bridji B, Benyoucef A, Meyer ME, Jalali K, Bardet S, et al. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). Eur J Nucl Med Mol Imaging 2013; 40: 542-4.

14. Song SY, Kim JH, Byu JS, Lee GH, Kim SB, Park SI, Song HY, Cho KJ, Ahn SD, Lee SW, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005; 63: 1053-9.

15. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, Lee JY, Lee KH, Kim BT. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 2010; 17: 115-22.

16. Choi ES, Ha SG, Kim HS, Ha JH, Paeng JC, Han I. Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma. Eur J Nucl Med Mol Imaging 2013; 40: 1836-42.

17. Moon SH, Hyun SH, Choi JY. Prognostic significance of volume-based PET parameters in cancer patients. Korean J Radiol 2013; 14: 1-12.

18. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 2012; 264: 559-66.

19. Arslan N, Tuncel M, Kuzhan O, Alagöz E, Budakoglu B, Ozet A, Ozgunen MA. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med 2011; 25: 406-13.

20. Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, Park K, Lee KH, Kim BT. Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsill: comparisons of volume-based metabolic parameters. Head Neck 2013; 35: 15-22.

21. Yoo J, Choi JY, Lee KT, Heo JS, Park SB, Moon SH, Choe YS, Lee KH, Kim BT. Prognostic significance of volume-based metabolic parameters by (18)F-FDG PET/CT in gallbladder carcinoma. Nucl Med Mol Imaging 2012; 46: 201-6.

22. Hatt M, Le Pogam A, Visvikis D, Pradier O, Cheze Le Rest C. Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer. J Nucl Med 2012; 53: 12-20.

23. Li YM, Lin Q, Zhao L, Wang LC, Sun L, Dai MM, Luo ZM, Zheng H, Wu H. Pre-treatment metabolic tumor volume and total lesion glycolysis are useful prognostic factors for esophageal squamous cell cancer patients. Asian Pac J Cancer Prev 2014; 15: 1369-73.

24. Aquino SL, Halpern EF, Kuester LB, Fischman AJ. FDG-PET and CT features of non-small cell lung cancer based on tumor type. Int J Mol Med 2007; 19: 495-9.